Literature DB >> 22082730

The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells.

Y Açil1, B Möller, P Niehoff, K Rachko, V Gassling, J Wiltfang, M J K Simon.   

Abstract

INTRODUCTION: Osteonecrosis of the jaw (ONJ) is an emerging condition in patients undergoing long-term administration of bisphosphonates (BP) for the treatment of osteoporosis and hypercalcaemia associated with malignancy, multiple myeloma, and metastatic breast and prostate cancers. This is a follow-up study, its purpose was to examine the effects in-vitro of intravenous zoledronic acid (ZOL) and pamidronate (PAM) and oral alendronate (FOS) on the human oral cavity using gingival fibroblasts and osteoblasts cells and, in addition, osteogenic sarcoma cells (SaOS-2-cells).
MATERIALS AND METHODS: Human gingival fibroblasts, osteoblasts and SaOS-2-cells were seeded on multiple 6-well plates at a density of 5 × 10(5)cells in a 4-week cell culture. Four different concentrations (1, 5, 10, 20 μM) of each BP (ZOL, PAM, FOS) and pyrophosphate were used in this study.
RESULTS: All BP decreased collagen production and lowered cell proliferation in-vitro. ZOL was the component with most inhibitory effect.
CONCLUSION: The findings in this study suggest that ZOL, PAM and FOS generally diminish cell proliferation and collagen production of human gingival fibroblasts, osteoblasts and SaOS-2-cells. The present follow-up study shows that not only ZOL and PAM but also FOS have a strong inhibitory effect on collagen production and cell survival in-vitro.
Copyright © 2011 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22082730     DOI: 10.1016/j.jcms.2011.10.024

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  20 in total

1.  Prevention of the surface resorption of bone grafts by topical application of bisphosphonate on different carrier materials.

Authors:  Björn Möller; Jörg Wiltfang; Yahya Acil; Matthias Gierloff; Sebastian Lippross; Hendrik Terheyden
Journal:  Clin Oral Investig       Date:  2014-02-23       Impact factor: 3.573

2.  Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy.

Authors:  Samantha Peiling Yang; Tae Won B Kim; Patrick J Boland; Azeez Farooki
Journal:  Oncologist       Date:  2017-03-08

3.  Bisphosphonates inhibit surface-mediated osteogenesis.

Authors:  Ethan M Lotz; Christoph H Lohmann; Barbara D Boyan; Zvi Schwartz
Journal:  J Biomed Mater Res A       Date:  2020-04-21       Impact factor: 4.396

4.  The effects of ozone application on genotoxic damage and wound healing in bisphosphonate-applied human gingival fibroblast cells.

Authors:  Sıdıka Sinem Akdeniz; E Beyler; Y Korkmaz; E Yurtcu; U Ates; K Araz; F I Sahin; O Y Torun
Journal:  Clin Oral Investig       Date:  2017-07-11       Impact factor: 3.573

5.  Periosteal microcirculatory reactions in a zoledronate-induced osteonecrosis model of the jaw in rats.

Authors:  Ágnes Janovszky; Andrea Szabó; Renáta Varga; Dénes Garab; Mihály Boros; Csilla Mester; Nikolett Beretka; Tamás Zombori; Hans-Peter Wiesmann; Ricardo Bernhardt; Imre Ocsovszki; Péter Balázs; József Piffkó
Journal:  Clin Oral Investig       Date:  2014-10-30       Impact factor: 3.573

6.  Nitric oxide-mediated cytotoxic effect induced by zoledronic acid treatment on human gingival fibroblasts.

Authors:  Marianna De Colli; Susi Zara; Viviana di Giacomo; Antonia Patruno; Guya Diletta Marconi; Marialucia Gallorini; Vincenzo Luca Zizzari; Giulia Tetè; Amelia Cataldi
Journal:  Clin Oral Investig       Date:  2014-10-30       Impact factor: 3.573

7.  PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells.

Authors:  Eduardo Anitua; Mar Zalduendo; María Troya; Gorka Orive
Journal:  Clin Oral Investig       Date:  2015-07-23       Impact factor: 3.573

8.  A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?

Authors:  T Hasegawa; A Kawakita; N Ueda; R Funahara; A Tachibana; M Kobayashi; E Kondou; D Takeda; Y Kojima; S Sato; S Yanamoto; H Komatsubara; M Umeda; T Kirita; H Kurita; Y Shibuya; T Komori
Journal:  Osteoporos Int       Date:  2017-04-27       Impact factor: 4.507

9.  Effects of zoledronic acid and geranylgeraniol on the cellular behaviour and gene expression of primary human alveolar osteoblasts.

Authors:  S Zafar; D E Coates; M P Cullinan; B K Drummond; T Milne; G J Seymour
Journal:  Clin Oral Investig       Date:  2016-01-22       Impact factor: 3.573

10.  Ionically Cross-Linked Polymer Networks for the Multiple-Month Release of Small Molecules.

Authors:  Patrick G Lawrence; Pritam S Patil; Nic D Leipzig; Yakov Lapitsky
Journal:  ACS Appl Mater Interfaces       Date:  2016-02-11       Impact factor: 9.229

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.